Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia
Version of Record online: 3 NOV 2011
© 2011 The Authors. Journal of Paediatrics and Child Health © 2011 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
Journal of Paediatrics and Child Health
Volume 48, Issue 8, pages 634–640, August 2012
How to Cite
Bhadri, V. A., Trahair, T. N. and Lock, R. B. (2012), Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia. Journal of Paediatrics and Child Health, 48: 634–640. doi: 10.1111/j.1440-1754.2011.02212.x
- Issue online: 6 AUG 2012
- Version of Record online: 3 NOV 2011
- Accepted for publication 2 May 2011.
Glucocorticoids (GCs), such as prednisolone and dexamethasone, are key components in multi-agent chemotherapy protocols used for the treatment of acute lymphoblastic leukaemia (ALL). Approximately 10% of children with ALL will respond poorly to GCs, and GC resistance is associated with a significantly inferior outcome. This review summarises the current knowledge of GC resistance in ALL, including the roles of the GC receptor and its co-chaperone molecules, the pro-apoptotic and pro-survival B-cell lymphoma 2 family members and alternative non-apoptotic mechanisms of cell death. It concludes with a discussion on therapeutic attempts to overcome GC resistance.